Emeryville, CA, July 15, 2009 — ADMEcell, Inc. today announced that it has entered into an exclusive agreement with Sovicell, Leipzig, Germany, to distribute the TRANSIL® product line for the North American market. The TRANSIL Membrane Permeability Kits and TRANSIL Protein Binding Kits are ready- to-use, innovative and state-of-the-art enabling tools to obtain rapid, accurate and reproducible pharmacokinetic data for drug candidates. The TRANSIL products are supplied in 96 well plates, ready-to-use, and no reagent preparation is required by our customers. They are ideal for automation.
“The TRANSIL Membrane Permeability Kits consists of TRANSIL Intestinal Absorption and TRANSIL Brain Absorptions Kits. The TANSIL Protein kits are TRANSIL HSA Binding, TRANSIL AGP and TRANSIL RSA Binding Kits. The TRANSIL kits are based on innovative mico beads technology that requires only 2 min incubation with samples which offers considerable savings of both cost and time,” says Sandy Koshkin, President of ADMEcell.
Sovicell, located in Leipzig, Germany, is a leader in providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable customers to obtain, rapid, accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.
The TRANSIL technology platform, based on a novel micro beads system, underpins its reliable membrane permeability and protein binding assays. While the range of SOVICYTE cell lines, with their in vivo-relevant metabolic properties, form the core of our drug metabolism and cytotoxicity assays.
ADMEcell, Inc. is an on-demand supplier of ready-to-use cell-based and other assay kits servicing the biotech and life sciences industries. Located in Emeryville, California, the company manufactures and distributes innovative and leading edge products through licensing and distribution agreements. ADMEcell’s product offerings enable rapid, sophisticated ready-to-use assays designed for in vitro therapeutic modeling and re-profiling. The common theme among the selected technologies is their leading edge nature and prominence within a chosen market. ADMEcell
Licensing and Distribution Opportunties
ADMEcell is currently considering the licensing and/or distribution of unique, state-of-the-art ready to use cell-based and other assays that have important applications in the drug discovery process. We are located in the San Francisco bay area and are partnered closely with a cell culture manufacturer to produce products under GMP. Please contact ADMEcell in confidence if you have a unique, compelling cell-based assay that is relevant to the biotechnology and life science marketplace, particularly to ADME-toxicology. www.admecell.com